Literature DB >> 24642342

Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes.

Naoki Hattori1, Maharani Retna Duhita2, Akira Mukai3, Megumi Matsueda3, Akira Shimatsu4.   

Abstract

BACKGROUND: Recently, insulin analogs have become widely used for the treatment of diabetes. The aim of this study was to determine differences in the antigenicity of insulin analogs and long-term changes in titers in patients with type 2 diabetes.
METHODS: Insulin antibodies were examined using polyethylene glycol and protein G methods in 381 patients with type 2 diabetes.
RESULTS: Insulin antibodies were detected in 48 of 118 patients (40.7%) who used insulin, and insulin glargine and aspart were more antigenic. Insulin antibodies were unexpectedly found in seven of 263 patients (2.7%) who had never used insulin. Serum insulin concentrations in patients with insulin antibodies were significantly higher than those without them. Two years after the initial evaluation, insulin antibodies were still positive in 92.7% of patients who used insulin; while, they disappeared in all patients who had never used insulin. A patient who stopped insulin injections 6years ago was found to be positive for insulin antibodies at the first evaluation as well as 2years later.
CONCLUSIONS: Insulin glargine and aspart induced insulin antibodies more frequently, and insulin antibodies remained in patients for a long time. Insulin antibodies should be suspected even in patients not currently on insulin therapy.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspart; Detemir; Glargine; Insulin antibodies; Lispro; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24642342     DOI: 10.1016/j.cca.2014.03.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years.

Authors:  Nandu Thalange; Abdullah Bereket; Lisbeth Bjerring Jensen; Line Conradsen Hiort; Valentina Peterkova
Journal:  Diabetes Ther       Date:  2016-09-06       Impact factor: 2.945

Review 2.  Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients.

Authors:  Xiaolei Hu; Fengling Chen
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

3.  Characteristics of OGTT and Correlation Between the Insulin to C-Peptide Molar Ratio, HOMA-IR, and Insulin Antibodies in T2DM Patients.

Authors:  Kai-Fang Hua; Ming-You Zhang; Yao Zhang; Bing-Jie Ren; Yan-Hui Wu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-09       Impact factor: 3.249

4.  Flying under the radar: treatment of refractory hyperglycemia.

Authors:  S M Kandel; J A Cosgriff
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-07-06

Review 5.  Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Authors:  Kjeld Hermansen; Mette Bohl; Anne Grethe Schioldan
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

6.  Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog.

Authors:  Chih-Ting Su; Yi-Chun Lin
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.